BIOFILM AND ITS ROLE IN BACTERIAL RESISTANCE TO ANTIBIOTICS

OUTLINE (for 50 marks)

1. Definition and Introduction
2. Historical Background
3. Composition of Biofilm
4. Stages of Biofilm Formation (with diagram)
5. Quorum Sensing
6. Mechanisms of Antibiotic Resistance in Biofilm (with flowchart)
7. ENT Relevance — Chronic Rhinosinusitis, Otitis Media, Tonsils
8. Organisms Involved
9. Clinical Implications
10. Management Strategies
11. Recent Advances
12. Summary/Conclusion

1. DEFINITION

"A biofilm is an aggregate of bacteria tolerant to treatment and the host defense." — Bjarnsholt et al., cited in Schwartz's Principles of Surgery, 11th Ed.

"Bacteria in the exopolysaccharide matrix may be protected from the host's immune mechanisms. Some of the bacteria within the biofilm show marked resistance to antimicrobials compared with the same strain grown free-living in broth." — Jawetz, Melnick & Adelberg's Medical Microbiology, 28th Ed.

2. HISTORICAL BACKGROUND

• Van Leeuwenhoek (1680s) first described microbial aggregates on tooth surfaces.
• The term "biofilm" was coined by J.W. Costerton in 1978.
• Donlan & Costerton (2002) — landmark review of biofilm in healthcare settings.
• Stoodley et al. (2002) — described biofilm as the predominant mode of microbial life.
• In ENT, Hall-Stoodley et al. (2006) demonstrated biofilms in chronic otitis media with effusion using FISH (fluorescence in situ hybridization).

3. COMPOSITION OF BIOFILM

"The EPS is composed of secreted proteins, glycans, lipids and the extravasated DNA of dying cells. This supports the microbial community and shields it from antimicrobial defenses, including antibodies, complement, and phagocytic cells." — Janeway's Immunobiology, 10th Ed.

4. STAGES OF BIOFILM FORMATION

DIAGRAM — Five Stages of Biofilm Formation

FLOWCHART — Biofilm Life Cycle

PLANKTONIC BACTERIA (Free-floating)
          │
          ▼ [Conditioning film on surface — host proteins, fibronectin]
    STAGE 1: REVERSIBLE ATTACHMENT
    (Bacteria adhere via flagella/pili/surface adhesins)
          │
          ▼ [Permanent anchor via surface proteins — MSCRAMM in S. aureus]
    STAGE 2: IRREVERSIBLE ATTACHMENT / MICROCOLONY FORMATION
    (Inhibition of motility; initial EPS secretion begins)
          │
          ▼ [Quorum sensing activated → gene expression shifts]
    STAGE 3: MATURATION STAGE I — EPS PRODUCTION
    (Extracellular polymeric substance forms protective matrix)
          │
          ▼ [3D mushroom-like structures; water channels form]
    STAGE 4: MATURE BIOFILM
    (Highly resistant, structured community; 800× more resistant to antibiotics)
          │
          ▼ [Enzymatic degradation of matrix via proteases/nucleases]
    STAGE 5: DISPERSAL
    (Bacteria shed as planktonic cells → seed new sites → cycle repeats)

• Attachment: within minutes
• Microcolony: 2–4 hours
• EPS production + antibiotic resistance: 6–12 hours
• Mature biofilm: 2–4 days
• Recovery after debridement: within 24 hours

5. QUORUM SENSING (QS)

Mechanism:

Bacteria produce small chemical signals → AUTOINDUCERS (AIs)
          │
          ▼
AIs accumulate as bacterial density increases
          │
          ▼
Threshold concentration of AIs reached → Binds receptor proteins
          │
          ▼
Gene expression altered in coordinated fashion
          │
          ▼
Biofilm-specific virulence genes activated:
  • EPS biosynthesis genes
  • Antibiotic efflux pumps
  • Toxin production
  • Motility suppression

• Gram-negative bacteria: Use N-acyl homoserine lactones (AHLs) as AIs (e.g., Pseudomonas aeruginosa — las/rhl systems)
• Gram-positive bacteria: Use oligopeptide autoinducers (e.g., S. aureus — agr system)
• Universal signal: Autoinducer-2 (AI-2) — cross-species communication

"Quorum sensing, where chemical signal molecules called autoinducers are produced depending on cell density and physiologic conditions, leading to the expression of specific genes in a coordinated fashion." — Rockwood & Green's Fractures in Adults, 10th Ed., 2025

6. MECHANISMS OF ANTIBIOTIC RESISTANCE IN BIOFILM

"Biofilm organisms are up to 800-fold less susceptible to antibiotics than planktonic organisms." — Rockwood & Green's Fractures in Adults, 10th Ed.

FLOWCHART — Mechanisms of Antibiotic Resistance

BIOFILM → ANTIBIOTIC RESISTANCE via FIVE MECHANISMS:

┌─────────────────────────────────────────────────────┐
│   MECHANISM 1: PHYSICAL BARRIER (EPS Matrix)        │
│   • EPS acts as diffusion barrier                   │
│   • Charged antibiotics bind to EPS components      │
│   • Hydrophobic drugs excluded by glycan layers     │
│   → Antibiotic never reaches bacteria               │
└─────────────────────────────────────────────────────┘
          │
┌─────────────────────────────────────────────────────┐
│   MECHANISM 2: ALTERED MICROENVIRONMENT             │
│   • Oxygen gradients within biofilm                 │
│   • Anaerobic zones → aminoglycosides ineffective   │
│   • Low pH in deeper layers → β-lactam inactivation │
│   • Nutrient depletion → metabolic slow-down        │
└─────────────────────────────────────────────────────┘
          │
┌─────────────────────────────────────────────────────┐
│   MECHANISM 3: PERSISTER CELLS                      │
│   • Subpopulation of metabolically dormant cells    │
│   • Antibiotic-tolerant (not resistant genetically) │
│   • Antibiotics target dividing cells only          │
│   • Persisters survive → repopulate after treatment │
└─────────────────────────────────────────────────────┘
          │
┌─────────────────────────────────────────────────────┐
│   MECHANISM 4: HORIZONTAL GENE TRANSFER (HGT)      │
│   • eDNA in matrix facilitates conjugation          │
│   • Resistance genes spread within biofilm          │
│   • Plasmids carrying resistance genes transferred  │
│   • Phenotypic AND genotypic plurality              │
└─────────────────────────────────────────────────────┘
          │
┌─────────────────────────────────────────────────────┐
│   MECHANISM 5: IMMUNE EVASION                       │
│   • EPS shields bacteria from opsonization          │
│   • Antibodies cannot penetrate matrix              │
│   • Complement activation blocked                   │
│   • Phagocytes "frustrated" → release ROS/proteases │
│   → Tissue damage WITHOUT bacterial killing         │
└─────────────────────────────────────────────────────┘

"The resistance to antimicrobial agents includes altered composition of extracellular polymeric substances, phenotypic and genotypic plurality — the latter allows virulence and bacterial resistance to drugs. The genetic plurality is passed horizontally among bacteria in the wound." — Schwartz's Principles of Surgery, 11th Ed.

Summary Table — Mechanisms

7. ENT RELEVANCE — BIOFILM IN HEAD AND NECK

A. Chronic Rhinosinusitis (CRS)

"The presence of biofilms on the sinus mucosa of CRS patients has been suggested as a mechanism for antibiotic resistance and the recurrence of inflammation after treatment. The biofilm hypothesis can be considered an offshoot of the staphylococcal superantigen hypothesis, as this is the organism most commonly identified in the biofilms of resistant CRS." — Cummings Otolaryngology, 7th Ed.

• Biofilms found on ethmoid mucosa in >50% of CRS patients undergoing FESS
• Organisms: S. aureus, S. epidermidis, H. influenzae, P. aeruginosa
• FISH and confocal laser scanning microscopy (CLSM) — gold standard for detection
• Explains why CRS recurs despite adequate antibiotic therapy

B. Chronic Otitis Media (COM)

• Hall-Stoodley (2006): Biofilms demonstrated on middle ear mucosa in children with otitis media with effusion (OME)
• H. influenzae, S. pneumoniae, M. catarrhalis — commonest biofilm-forming organisms in otitis
• Biofilm on tympanostomy tubes — contributes to tube blockage and persistent discharge
• Explains persistence of OME despite multiple antibiotic courses

C. Tonsils and Adenoids

• Biofilms found on tonsillar crypts — recurrent tonsillitis organisms (Streptococcus, Bacteroides)
• Adenoid biofilms serve as a reservoir for sinonasal pathogens
• Dhingra emphasizes the role of tonsillar biofilm in recurrent tonsillitis and antibiotic failure

D. Dental Plaque (Oral Biofilm)

"Dental plaque is the most prevalent and densest of human biofilms. It forms in stages and layers. The biofilm fastens nutrient and growth regulatory relationships between its members and provides a shield from the outside. There are thought to be 300–400 bacterial species present in mature dental plaque."

8. ORGANISMS COMMONLY FORMING BIOFILM IN ENT

9. CLINICAL IMPLICATIONS

Biofilm Diagram — Immune Evasion

• Biofilms explain treatment failure in chronic infections
• In cystic fibrosis: P. aeruginosa biofilm in airways is the principal cause of morbidity and mortality — Jawetz Medical Microbiology, 28th Ed.
• Prosthetic joint and orthopedic implant infections: Up to 65% caused by biofilm-producing organisms — Rockwood & Green's, 10th Ed.
• Catheter-associated infections (CAUTI, CLABSI): S. epidermidis and S. aureus biofilm
• In chronic wounds (diabetic, venous): >60% harbor biofilm — Schwartz's Surgery, 11th Ed.

10. MANAGEMENT OF BIOFILM INFECTIONS

FLOWCHART — Treatment Approach

SUSPECTED BIOFILM INFECTION
          │
          ▼
DIAGNOSIS:
  • CLSM (Confocal Laser Scanning Microscopy)
  • FISH (Fluorescence In-Situ Hybridization)
  • SEM (Scanning Electron Microscopy)
  • Synovial fluid culture with sonication
          │
          ▼
STEP 1: PHYSICAL DISRUPTION
  • Surgical debridement (most effective)
  • Debridement weekly in wounds
  • FESS in CRS — removes biofilm-laden mucosa
  • Implant removal where feasible
          │
          ▼
STEP 2: ANTIMICROBIAL THERAPY
  (Post-disruption — while biofilm disrupted)
  • Rifampicin — penetrates biofilm matrix
  • Fluoroquinolones — moderate biofilm penetration
  • Fosfomycin — inhibits EPS synthesis
  • Topical silver/iodine/honey — wound biofilms
  • Prolonged IV antibiotics for implant infections
          │
          ▼
STEP 3: PREVENTION OF RECURRENCE
  • Anti-biofilm coated implants (silver, rifampicin-coated)
  • Nasal irrigation (saline) in CRS
  • Probiotics (competitive exclusion)
  • Anti-quorum sensing agents (experimental)

11. RECENT ADVANCES (2020–2025)

1. Anti-Quorum Sensing (Anti-QS) Therapy: Quorum quenching enzymes (e.g., lactonases that degrade AHLs); halogenated furanones — block QS signaling to prevent biofilm formation without selective pressure for resistance.
2. Bacteriophage Therapy: Phages can penetrate and dissolve EPS matrix via phage-encoded depolymerases; phage cocktails active against MRSA and P. aeruginosa biofilms in clinical trials (2022–2024).
3. Dispersin B (DspB): Enzyme that degrades poly-N-acetylglucosamine (PNAG) in staphylococcal and H. influenzae biofilms — ongoing trials.
4. Nano-particle-based Drug Delivery: Antibiotic-loaded nanoparticles (silver, chitosan, PLGA) penetrate EPS — overcome diffusion barrier limitation.
5. Photodynamic Inactivation (PDI): Light-activated photosensitizers generate ROS that kill biofilm bacteria — studied in chronic sinusitis and wound biofilms.
6. DNase (Dornase alfa): Degrades eDNA in EPS matrix — used in CF lungs; being studied for sinus and wound biofilms.
7. Biofilm-specific diagnostics: 16S rRNA metagenomic sequencing replacing conventional cultures for detecting multispecies biofilm communities in CRS and OME.
8. MBEC (Minimum Biofilm Eradication Concentration) assay — recognized as superior to MIC for guiding antibiotic dosing in biofilm infections.

12. COMPARISON: PLANKTONIC vs BIOFILM BACTERIA

SUMMARY DIAGRAM — Biofilm & Antibiotic Resistance (Master Flowchart)

BACTERIA ENCOUNTER SURFACE
(sinus mucosa / implant / wound / middle ear mucosa)
          │
          ▼
CONDITIONING FILM — Host proteins (fibronectin, fibrinogen) coat surface
          │
          ▼
INITIAL ATTACHMENT — via adhesins, pili, flagella (minutes)
          │
          ▼
MICROCOLONY FORMATION — irreversible attachment (2–4 hours)
          │
          ▼
QUORUM SENSING ACTIVATED — autoinducers accumulate
          │
          ▼
EPS MATRIX SECRETION — glycocalyx, proteins, eDNA (6–12 hours)
          │
   ┌──────┴──────────────────────────────────┐
   ▼                                         ▼
MATURE BIOFILM                        PERSISTER CELLS FORMED
(mushroom colonies, water channels)   (dormant, treatment-tolerant)
   │
   ▼
ANTIBIOTIC APPROACHES BLOCKED BY:
   ├─→ EPS diffusion barrier
   ├─→ Anaerobic/low pH microenvironment
   ├─→ Efflux pumps (QS-regulated)
   ├─→ Horizontal gene transfer (resistance plasmids)
   └─→ Persister cell dormancy
          │
          ▼
HOST IMMUNE RESPONSE FRUSTRATED:
   ├─→ Complement blocked by EPS
   ├─→ Phagocytes cannot ingest bacteria
   └─→ Frustrated neutrophils release ROS → TISSUE DAMAGE
          │
          ▼
CHRONIC INFECTION ESTABLISHED
(CRS / COM / Chronic wounds / Osteomyelitis / Device infections)
          │
          ▼
DISPERSAL → New planktonic cells shed → Spread to new sites

KEY REFERENCES FOR RGUHS

CONCLUSION